India Sets Out Modalities Of Perpetual Licensing Initiative
Executive Summary
India has outlined key aspects of its recently introduced perpetual licensing system, including initial modalities around joint inspections of manufacturing units by central and state drug inspectors.
You may also be interested in...
India’s Risk-Based Inspection Plan: Well Begun?
India's CDSCO is taking definitive steps to strengthen the regulatory regime and enforcement, including across areas such as data integrity, against the backdrop of industry's patchy manufacturing compliance.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet